Unknown

Dataset Information

0

Short-Acting β2-Agonist Use Could Be a Confounding Factor for Interpreting Increased IL-6.

ABSTRACT:

SUBMITTER: Nannini LJ 

PROVIDER: S-EPMC7605194 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Short-Acting β<sub>2</sub>-Agonist Use Could Be a Confounding Factor for Interpreting Increased IL-6.

Nannini Luis J LJ  

American journal of respiratory and critical care medicine 20201101 9

Similar Datasets

Unknown Short-acting β<sub>2</sub> -agonist use and asthma exacerbations in Swedish children: A SABINA Junior study.
| S-EPMC9828275 | biostudies-literature
Unknown Short-acting β<sub>2</sub>-agonist prescription patterns for asthma management in the SABINA III primary care cohort.
| S-EPMC9522811 | biostudies-literature
Unknown Short-acting β<sub>2</sub>-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III.
| S-EPMC9161536 | biostudies-literature
Unknown The Burden of Short-Acting β<sub>2</sub>-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.
| S-EPMC8280008 | biostudies-literature
Unknown Short-acting β<sub>2</sub>-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.
| S-EPMC9068976 | biostudies-literature
Unknown Over-the-counter short-acting β<sub>2</sub>-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study.
| S-EPMC11530521 | biostudies-literature
Unknown A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β<sub>2</sub>-Agonist (LABA) Combinations in COPD.
| S-EPMC6964204 | biostudies-literature
Unknown Prediction of short-acting beta-agonist usage in patients with asthma using temporal-convolutional neural networks.
| S-EPMC10602590 | biostudies-literature
Unknown New Asthma Diagnosis Codes or Short-Acting β&lt;sub&gt;2&lt;/sub&gt; Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018-2023.
| S-EPMC12666392 | biostudies-literature
Unknown Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma.
| S-EPMC9438376 | biostudies-literature